Literature DB >> 28489472

Enalapril maleate orally disintegrating tablets: tableting and in vivo evaluation in hypertensive rats.

Hesham M Tawfeek1, Waleed Faisal2, Ghareb M Soliman3,4.   

Abstract

The aim of this study was to develop orally disintegrating tablets (ODTs) for enalapril maleate (EnM) to facilitate its administration to the elderly or other patients having dysphagia. Compatibility between EnM and various excipients was studied using differential scanning calorimetry. ODTs of EnM were prepared by direct compression of EnM mixtures with various superdisintegrants. The tablets were evaluated for physical properties including drug content, hardness, friability, disintegration time, wetting time, and drug release. The antihypertensive effect of the optimum EnM ODTs was evaluated in vivo in hypertensive rats and compared with commercial EnM formulation. EnM ODTs had satisfactory results in terms of drug content and friability. Tablet wetting and disintegration were fast and dependent on the used superdisintegrant where croscarmellose showed the fastest wetting and disintegration time of ∼7 s. EnM release from the tablets was rapid where complete release was obtained in 10-15 min. Selected EnM ODTs rapidly and efficiently reduced the rat's blood pressure to its normal value within 1 h, compared with 4 h for EnM commercial formulation. These results confirm that EnM ODTs could find application in the management of hypertension in the elderly or other patients having dysphagia.

Entities:  

Keywords:  Enalapril maleate; hypertension; orally disintegrating tablets; superdisintegrants

Mesh:

Substances:

Year:  2017        PMID: 28489472     DOI: 10.1080/10837450.2017.1329318

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  7 in total

1.  A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study.

Authors:  Mahmoud H Teaima; Khaled M Abdel-Haleem; Rewan Osama; Mohamed A El-Nabarawi; Osama S Elnahas
Journal:  Drug Des Devel Ther       Date:  2021-10-07       Impact factor: 4.162

2.  Design and optimization of silymarin loaded in lyophilized fast melt tablets to attenuate lung toxicity induced via HgCl2 in rats.

Authors:  Nermin M Sheta; Sylvia A Boshra; Mohamed A Mamdouh; Khaled M Abdel-Haleem
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

3.  Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization.

Authors:  Noha N Atia; Hesham M Tawfeek; Azza H Rageh; Marwa R El-Zahry; Ahmed Abdelfattah; Mahmoud A Younis
Journal:  Saudi Pharm J       Date:  2019-02-05       Impact factor: 4.330

4.  Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization.

Authors:  Hesham M Tawfeek; Yasser A Hassan; Mohammed F Aldawsari; Mohamed H Fayed
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-05

5.  Bioequivalence of Esaxerenone Conventional Tablet and Orally Disintegrating Tablet: Two Single-Dose Crossover Studies in Healthy Japanese Men.

Authors:  Akifumi Kurata; Takashi Eto; Junko Tsutsumi; Yoshiyuki Igawa; Yasuhiro Nishikawa; Hitoshi Ishizuka
Journal:  Clin Pharmacol Drug Dev       Date:  2022-03-21

6.  Spironolactone-Loaded LeciPlexes as Potential Topical Delivery Systems for Female Acne: In Vitro Appraisal and Ex Vivo Skin Permeability Studies.

Authors:  Ayman Salama; Mohamed Badran; Mohammed Elmowafy; Ghareb M Soliman
Journal:  Pharmaceutics       Date:  2019-12-25       Impact factor: 6.321

7.  Studying the Complex Formation of Sulfonatocalix[4]naphthalene and Meloxicam towards Enhancing Its Solubility and Dissolution Performance.

Authors:  Tayel A Al Hujran; Mousa K Magharbeh; Samer Al-Gharabli; Rula R Haddadin; Manal N Al Soub; Hesham M Tawfeek
Journal:  Pharmaceutics       Date:  2021-06-30       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.